Company Name: Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company is engaged in the development of treatments for severe and ultra-rare diseases. The company’s Soliris® is a terminal complement inhibitor designed to treat atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company’s metabolic franchise includes enzyme replacement therapies designed to treat hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). The company’s pipeline includes product candidates in several therapeutic areas.

Ticker Symbol: ALXN (NASDAQ)

Company Website:

Social Media: Alexion Pharmaceuticals LinkedIn Page

Headquarters: New Haven, Connecticut